Double immunotherapy attack shows promise in tough lung cancer
NCT ID NCT04665856
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study tests whether adding tiragolumab (an experimental immunotherapy) to the standard combination of atezolizumab plus chemotherapy can help people with untreated, widespread small cell lung cancer live longer without their disease worsening. About 123 participants in China received either the triple therapy or a placebo version. The main goals are to see if the new combo delays cancer growth and improves overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tiragolumab (an immunotherapy drug) combined with atezolizumab (Tecentriq) and chemotherapy (carboplatin and etoposide)
- What this could lead to
- If successful, this combination could become a new standard first-line treatment for extensive-stage small cell lung cancer, potentially improving how long patients live without their cancer growing.
- What could go wrong
- This is a Phase 3 trial, but it only enrolled 123 people in China, so results may not apply to everyone. Adding another immunotherapy (tiragolumab) may increase side effects without guaranteeing better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Beijing Chest Hospital
Beijing, 101149, China
-
Cancer Center of Guangzhou Medical University
Guangzhou, 510000, China
-
Cancer Hospital of Shantou University Medical College
Shantou, 515041, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200120, China
-
Fujian Provincial Cancer Hospital
Fuzhou, 350014, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Henan Cancer Hospital
Zhengzhou, 450008, China
-
Shanghai Chest Hospital
Shanghai, 200000, China
-
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, 310016, China
-
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, 330006, China
-
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, 430022, China
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
Zhongshan Hospital Fudan University
Shanghai, 200032, China
-
the First Affiliated Hospital of Bengbu Medical College
Bengbu, 233000, China
-
the First Hospital of Jilin University
Changchun, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Can head radiation stop lung cancer from spreading to the brain?
- New hope for tough lung cancer: drug plus radiation combo shows promise in early trial
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- New hope for tough lung cancer: early trial launches in china
- Laser and Light-Sensitive drug shrink lung tumors in early trial